Is Charles River Laboratories Stock Underperforming the Nasdaq?

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) is a contract research organization. It provides drug discovery, non-clinical development, and safety testing services. With a market cap of $7.6 billion, Charles Rivers operates through Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions segments.

Companies worth between $2 billion and $10 billion are generally described as "mid-cap stocks." CRL fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the diagnostics and research industry.